Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

GLP-1RA therapy significantly reduces the risk for new-onset heart failure in patients with T2D or obesity, regardless of weight loss.

Primary hyperparathyroidism is associated with increased long-term risks for hypertension, type 2 diabetes, and cardiovascular disease.

FDA grants Priority Review to teplizumab for patients aged 1 to 7 years with stage 2 type 1 diabetes to delay stage 3 onset.

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

For patients at high cardiovascular risk with obesity, semaglutide is associated with reduced burden of total hospital admissions.

For patients with hypertension, initiating treatment with an ARB is associated with the best long-term class persistence.

Accelerated linear growth and weight gain from birth to 4 years of age are associated with earlier pubertal onset, particularly in girls.

The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

Withdrawal of tirzepatide treatment in adults with obesity who have achieved initial weight loss is associated with substantial weight regain and a corresponding reversal of the positive ...

The progression to T2D or cancer and the probability of death following prediabetes diagnosis vary according to age at prediabetes diagnosis, with most younger individuals remaining in the prediabetes ...

Persistent hormonal imbalances due to inadequately treated maternal hypothyroidism throughout pregnancy, especially combined chronic and gestational dysfunction, is associated with a significantly ...